ENDRA Life Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021
- Tech mega-caps knock 1% off Nasdaq; banks lift Dow
- EV Company Polestar To Go Public Via $20 Billion SPAC Deal
- Amazon (AMZN) Price Target Lowered at Morgan Stanley Amid Rising Logistics Workforce Costs, Analyst Expects Stock to be Range Bound in Near Term
- Brent oil nears $80 a barrel on tight supply
- Some Apple (AAPL) and Tesla (TSLA) Suppliers Suspend Production in China For a Few Days
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
ANN ARBOR, MI / ACCESSWIRE / August 2, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the second quarter of 2021 on Thursday, August 12, 2021 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions. Participation instructions are as follows:
Replay Dial-in Numbers
Replay Passcode: 42091
The telephone replay will be available through 4:30 p.m. Eastern time on August 19, 2021
A live audio webcast will be available through the Events & Presentations page of the Investors section of the company's website at www.endrainc.com. A replay of the webcast will be available on the website for 60 days.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS«), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS┬« is designed to work in concert with 400,000 cart-based ultrasound systems in use globally today. TAEUS┬« is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS┬«, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visitwww.endrainc.com.
Investor Relations Contact:
LHA Investor Relations
SOURCE: ENDRA Life Sciences Inc.
View source version on accesswire.com:
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Civis Analytics Raises $30.7 Million in Series B Funding
- XPart S.A.: Announcement to the Stockholders of XPart S.A. (also stockholders of Ita├║ Unibanco Holding S.A.)
- Rexall follows disturbing trend; refuses to honour union contract language and recognize National Day for Truth and Reconciliation as a statutory holiday for its unionized employees
Create E-mail Alert Related CategoriesAccesswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!